Free Trial
NASDAQ:SRPT

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Sarepta Therapeutics logo
$99.69 -3.34 (-3.24%)
Closing price 03/10/2025 04:00 PM Eastern
Extended Trading
$98.75 -0.94 (-0.94%)
As of 03/10/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Key Stats

Today's Range
$98.82
$102.15
50-Day Range
$99.69
$127.89
52-Week Range
$98.82
$173.25
Volume
1.64 million shs
Average Volume
923,232 shs
Market Capitalization
$9.67 billion
P/E Ratio
79.75
Dividend Yield
N/A
Price Target
$170.41
Consensus Rating
Moderate Buy

Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Remove Ads

Sarepta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

SRPT MarketRank™: 

Sarepta Therapeutics scored higher than 96% of companies evaluated by MarketBeat, and ranked 30th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 18 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Sarepta Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sarepta Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sarepta Therapeutics are expected to grow by 309.74% in the coming year, from $2.67 to $10.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sarepta Therapeutics is 79.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.49.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sarepta Therapeutics is 79.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.92.

  • Price to Book Value per Share Ratio

    Sarepta Therapeutics has a P/B Ratio of 10.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Sarepta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.58% of the float of Sarepta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently decreased by 2.57%, indicating that investor sentiment is improving.
  • Dividend Yield

    Sarepta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sarepta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.58% of the float of Sarepta Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently decreased by 2.57%, indicating that investor sentiment is improving.
  • News Sentiment

    Sarepta Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.
  • Search Interest

    23 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 92% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,310,820.00 in company stock.

  • Percentage Held by Insiders

    Only 7.70% of the stock of Sarepta Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sarepta Therapeutics' insider trading history.
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Biotech stocks
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? (SRPT)
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
A Closer Look At Sarepta Therapeutics' Earnings
Sarepta files automatic mixed securities shelf
See More Headlines

SRPT Stock Analysis - Frequently Asked Questions

Sarepta Therapeutics' stock was trading at $121.59 at the beginning of 2025. Since then, SRPT stock has decreased by 18.0% and is now trading at $99.69.
View the best growth stocks for 2025 here
.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. Sarepta Therapeutics's quarterly revenue was up 38.9% compared to the same quarter last year.

Sarepta Therapeutics subsidiaries include Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc..

Sarepta Therapeutics' top institutional shareholders include Vanguard Group Inc. (9.51%), Capital International Investors (9.11%), Janus Henderson Group PLC (4.53%) and Farallon Capital Management LLC (3.00%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Stephen Mayo and Kathryn Jean Boor.
View institutional ownership trends
.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN).

Company Calendar

Last Earnings
8/07/2024
Today
3/10/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,314
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$170.41
High Stock Price Target
$230.00
Low Stock Price Target
$75.00
Potential Upside/Downside
+70.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
23 Analysts

Profitability

Trailing P/E Ratio
79.75
Forward P/E Ratio
37.34
P/E Growth
N/A
Net Income
$-535,980,000.00
Pretax Margin
7.89%

Debt

Sales & Book Value

Annual Sales
$1.90 billion
Price / Cash Flow
N/A
Book Value
$9.19 per share
Price / Book
10.85

Miscellaneous

Free Float
88,165,000
Market Cap
$9.67 billion
Optionable
Optionable
Beta
0.79

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:SRPT) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners